Celator Pharmaceuticals Enrolls First Patient In Its Phase 2 Study Of CPX-351 In Acute Myeloid Leukemia In First Relapse

News — By on April 7, 2009 at 6:35 am

PRINCETON, N.J. — Celator Pharmaceuticals today announced that the first patient has been treated in its Phase 2 multicenter, randomized, open-label clinical trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection versus intensive salvage therapy in adult patients (up to 60 years old) with acute myeloid leukemia in first relapse. As previously announced, the study is being supported through a partnership with The Leukemia & Lymphoma Society (LLS). The first patient was enrolled by Maureen Cooper, M.D., at St. Francis Hospital in Beech Grove, Indiana. “We are pleased to be participating in this study and eager to collect additional clinical evidence demonstrating the benefit of delivering and maintaining a synergi…

Please read the complete article and let us know what you think below.

Leave a Reply

Trackbacks

Leave a Trackback